Comment from UCB Inc.

Summary: UCB, Inc., a global biopharmaceutical company, expresses strong support for the FDA's pilot program to optimize early-phase clinical trials using AI. They provide specific recommendations on trial design, evaluation metrics, and the importance of open-source tools and collaborative learning to improve patient outcomes and trial efficiency.